The Wegovy pill is here! Available through early access at Metabolic.
Following international rollout of oral semaglutide, Metabolic is among the first in the UAE to offer early access as part of a physician-led metabolic health program.
Join the priority access list
Fill out the form and our team will get in touch with you shortly.
A simpler way to take GLP-1 therapy
Unlike injectable GLP-1 treatments, the Wegovy pill:
- Is taken once daily in the morning
- Requires no injections
- Fits into existing daily routines
- Is taken before food or drink, with simple timing guidance
For many patients, the shift to an oral format reduces friction in starting and staying consistent with treatment.
Because in real-world care, consistency often matters as much as initiation.
The Metabolic approach:
Not just a pill. A structured program.
At Metabolic, the Wegovy pill is not offered as a standalone medication. It is integrated into a comprehensive, physician-led metabolic program that includes:
Doctor-led assessment and ongoing supervision
Personalized dosing and titration plans
Regular metabolic blood testing and monitoring
Nutrition and lifestyle guidance
Body composition and health tracking
Continuous clinical follow-up and support
This ensures treatment is guided, measurable, and sustainable over time.
Designed for long-term metabolic management
For many patients, the primary challenge in weight management is not initial response but long-term maintenance.
Clinical evidence in GLP-1 therapies shows that discontinuation is often associated with weight regain, highlighting the importance of structured continuation strategies.
The Wegovy pill supports a more flexible approach to long-term care, particularly for patients who:
- Want to stick to semaglutide but prefer a non-injectable maintenance option
- Are transitioning from injectable GLP-1 therapies
- Prefer a pill with lower side effects (clinically proven)
- Require a lower-burden, daily oral regimen
- Are focused on long-term metabolic stability under medical supervision
At Metabolic, this is supported through physician-guided pathways designed around continuity of care and individual response.
Clinical evidence in context
In large-scale clinical trials of oral semaglutide:
- Average weight loss reached ~17% over approximately 64 weeks in patients receiving treatment alongside lifestyle intervention
- A significant proportion of patients achieved clinically meaningful weight reduction
- Improvements were also observed in cardiometabolic risk markers such as waist circumference and glycaemic parameters
These outcomes were achieved under structured medical supervision and lifestyle support.
Why structured care matters
Metabolic’s clinical experience continues to show that outcomes are strongly influenced by consistency and engagement.
Patients enrolled in structured programs demonstrate:
- Is taken once daily in the morning
- Requires no injections
- Fits into existing daily routines
- Is taken before food or drink, with simple timing guidance
This is particularly relevant in chronic metabolic conditions, where ongoing management is key.